[S7] シンポジウム7「Vector Development」

[S7-3] The safety and efficacy of pre-treatment with imlifidase prior to adeno associated virus (AAV)-based gene therapy in non-human primates with pre-existing anti-AAVrh74 antibodies

^○Rachael A Potter¹, Sohrab Khan¹, John Snedeker¹, Kaitlin Adegboye¹, Alex Haile¹, Behman Sayanjali¹, Nicole Pukos¹, Kyle Cochran¹, Jen Ahner¹, Ting Su¹, Nathalie Uzc?tegui², Yvonne Stenberg², Catja Freiburghaus², Lena Winstedt², Louise R Rodino-Klapac¹ (1.Sarepta Therapeutics, Inc., Cambridge, MA, USA, 2.Hansa Biopharma, Lund, Skane County, Sweden)